TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111
5 INDUSTRY INSIGHTS 112
6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114
7 MARKET OVERVIEW 117
7.1 DRIVERS 119
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127
8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128
8.1 OVERVIEW 129
8.2 IMAGING 133
8.2.1 COMPUTED TOMOGRAPHY 134
8.2.2 ULTRASOUND 134
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
8.2.4 ANGIOGRAPHY 134
8.2.5 X-RAY 134
8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
8.4.1 FINE NEEDLE ASPIRATION 136
8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
8.5.1 AQUAPORIN 1 (AQP1) 138
8.5.2 PERILIPIN (PLIN2) 138
8.5.3 N-METHYLTRANSFERASE (NMNT) 138
8.5.4 L-PLASTIN (LCP-1) 138
8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139
9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141
9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147
10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148
10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
10.2.1 IMAGING 154
10.2.2 BLOOD TEST 154
10.2.3 BIOPSY 154
10.2.4 BIOMARKER TEST 154
10.2.5 GENETIC TEST 154
10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
10.3.1 IMAGING 156
10.3.2 BLOOD TEST 156
10.3.3 BIOPSY 156
10.3.4 BIOMARKER TEST 156
10.3.5 GENETIC TEST 156
10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
10.4.1.1 IMAGING 158
10.4.1.2 BLOOD TEST 158
10.4.1.3 BIOPSY 158
10.4.1.4 BIOMARKER TEST 158
10.4.1.5 GENETIC TEST 158
10.4.1.6 OTHERS 158
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
10.4.2.1 IMAGING 159
10.4.2.2 BLOOD TEST 159
10.4.2.3 BIOPSY 159
10.4.2.4 BIOMARKER TEST 159
10.4.2.5 GENETIC TEST 159
10.4.2.6 OTHERS 159
11 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160
11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
11.2.1 IMAGING 166
11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
11.3.1 NEXT GENERATION SEQUENCING 168
11.3.2 MICROARRAYS 168
11.3.3 PCR 169
11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
11.4.1 RENAL CANCER PANELS 171
11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171
12 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172
12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179
13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181
13.1 OVERVIEW 182
13.2 SCREENING 185
13.2.1 INSTRUMENT BASED PRODUCTS 186
13.2.2 PLATFORM BASED PRODUCTS 186
13.2.3 KITS AND REAGENTS 186
13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
13.3.1 INSTRUMENT BASED PRODUCTS 187
13.3.2 PLATFORM BASED PRODUCTS 187
13.3.3 KITS AND REAGENTS 187
13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
13.4.1 INSTRUMENT BASED PRODUCTS 189
13.4.2 PLATFORM BASED PRODUCTS 189
13.4.3 KITS AND REAGENTS 189
13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
13.5.1 INSTRUMENT BASED PRODUCTS 190
13.5.2 PLATFORM BASED PRODUCTS 190
13.5.3 KITS AND REAGENTS 190
13.5.4 OTHER CONSUMABLES 191
14 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192
14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199
15 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200
15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205
16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206
16.1 MIDDLE EAST AND AFRICA 207
16.1.1 SOUTH AFRICA 220
16.1.2 SAUDI ARABIA 227
16.1.3 BAHRAIN 235
16.1.4 U.A.E. 242
16.1.5 EGYPT 250
16.1.6 ISRAEL 258
16.1.7 KUWAIT 266
16.1.8 OMAN 274
16.1.9 QATAR 282
16.1.10 REST OF MIDDLE EAST AND AFRICA 290
17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 291
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 291
18 SWOT ANALYSIS 292
19 COMPANY PROFILE 293
19.1 CANON MEDICAL SYSTEMS CORPORATION 293
19.1.1 COMPANY SNAPSHOT 293
19.1.2 REVENUE ANALYSIS 293
19.1.3 COMPANY PROFILE 294
19.1.4 PRODUCT PORTFOLIO 294
19.1.5 RECENT DEVELOPMENT 294
19.2 KONINKLIJKE PHILIPS N.V. 295
19.2.1 COMPANY SNAPSHOT 295
19.2.2 REVENUE ANALYSIS 295
19.2.3 COMPANY PROFILE 296
19.2.4 PRODUCT PORTFOLIO 296
19.2.5 RECENT DEVELOPMENTS 297
19.3 GENERAL ELECTRIC COMPANY 298
19.3.1 COMPANY SNAPSHOT 298
19.3.2 REVENUE ANALYSIS 298
19.3.3 COMPANY PROFILE 299
19.3.4 PRODUCT PORTFOLIO 299
19.3.5 RECENT DEVELOPMENTS 300
19.4 SIEMENS HEALTHCARE GMBH 301
19.4.1 COMPANY SNAPSHOT 301
19.4.2 REVENUE ANALYSIS 301
19.4.3 COMPANY PROFILE 302
19.4.4 PRODUCT PORTFOLIO 302
19.4.5 RECENT DEVELOPMENT 303
19.5 GRAIL 304
19.5.1 COMPANY SNAPSHOT 304
19.5.2 PRODUCT PORTFOLIO 304
19.5.3 RECENT DEVELOPMENTS 304
19.6 AMBRY GENETICS 306
19.6.1 COMPANY SNAPSHOT 306
19.6.2 PRODUCT PORTFOLIO 306
19.6.3 RECENT DEVELOPMENT 306
19.7 BIOVENDOR R&D 307
19.7.1 COMPANY SNAPSHOT 307
19.7.2 PRODUCT PORTFOLIO 307
19.7.3 RECENT DEVELOPMENT 307
19.8 BLUEPRINT GENETICS OY. 308
19.8.1 COMPANY SNAPSHOT 308
19.8.2 PRODUCT PORTFOLIO 308
19.8.3 RECENT DEVELOPMENT 308
19.9 CD GENOMICS 309
19.9.1 COMPANY SNAPSHOT 309
19.9.2 PRODUCT PORTFOLIO 309
19.9.3 RECENT DEVELOPMENT 309
19.10 CENTOGENE N.V. 310
19.10.1 COMPANY SNAPSHOT 310
19.10.2 REVENUE ANALYSIS 310
19.10.3 PRODUCT PORTFOLIO 311
19.10.4 RECENT DEVELOPMENT 311
19.11 CREATIVE DIAGNOSTICS 312
19.11.1 COMPANY SNAPSHOT 312
19.11.2 PRODUCT PORTFOLIO 312
19.11.3 RECENT DEVELOPMENT 312
19.12 FUJIFILM CORPORATION 313
19.12.1 COMPANY SNAPSHOT 313
19.12.2 REVENUE ANALYSIS 313
19.12.3 PRODUCT PORTFOLIO 314
19.12.4 RECENT DEVELOPMENTS 314

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.